Abstract: The G-protein-coupled receptor kinase 2 (GRK2) plays a major role in cardiovascular diseases, and its expression is increased in heart failure. However, only little is known about factors being involved in up-regulation of GRK2 expression through transcriptional regulation of its promoter. Since the transcription factor early-growth response 1 (EGR-1) is also up-regulated in patients with heart failure, we tested the hypothesis that EGR-1 regulates GRK2 transcription. Stimulation of immortalized rat cardiomyocytes (H9c2) with phorbol 12-myristate 13-acetate (PMA) resulted in up-regulation of Egr-1 and subsequently of Grk2 mRNA expression, with maximum Grk2 expression (p = 0.008) 5 hr after PMA stimulation and being abolished by actinomycin D, indicating a transcriptional mechanism. To identify naturally occurring variants affecting promoter transcriptional activity, we identified a novel G(-43)A polymorphism (rs182084609), which surrounded a putative EGR-1-binding site. While the minor A allele frequency was rare (0.02), this variant was used to explore regulation by EGR-1 and promoter construct with altered alleles at nt-43 were subjected of reporter assays in human embryonic kidney cells (Hek293). Here, EGR-1 over-expression resulted in a more than twofold increase in GRK2 promoter activity but only in the presence of the G-allele (p = 0.04). In electrophoretic mobility shift assays, EGR-1 over-expression resulted in a specific binding of transcription factors only to the G oligonucleotide. Finally, EGR-1 over-expression resulted in increased GRK2 mRNA expression (p = 0.03). We identified EGR-1 as a regulator of GRK2 transcription. Suppression of GRK2 expression by inhibition of EGR-1 binding to GRK2 might be a promising approach to mitigate adrenergic desensitization.
G-protein-coupled receptor kinases (GRKs) have a major biological impact since they modulate G-protein-coupled receptors (GPCRs) [1] , in particular b-adrenergic receptors (b-ARs), and have a pivotal role in cardiovascular disease. In heart failure, increased cardiac GRK2 expression and activation leads to increased phosphorylation and desensitization of b-ARs, subsequently decreasing adrenergic signalling via the G s protein-Adenylcyclase-Proteinkinase A pathway, and consequently reduced myocardial contractility [2] . Elevated levels and activity of GRK2 are able to promote the dysfunction of both cardiac and adrenal a-and b-ARs and to dysregulate other protective pathways, such as sphingosine 1-phospate [3, 4] . Moreover, recent studies suggest that GRK2 can signal independently from GPCRs, in a 'non-canonical' manner, via interaction with non-GPCR molecules or via its mitochondrial localization [5] , therefore underscoring its biological role in cellular signal transduction.
Since heart failure is one of the leading causes of death with enormous healthcare costs, the identification of molecular pathways involved in the development and progression of this disease is of major importance to ultimately identify new therapeutic targets. Here, different compounds have been developed for targeting GRK2 via pharmacological inhibition or gene therapy [6] . However, despite the role of GRK2 to be a central culprit in heart failure development, only little is known about the transcriptional regulation of the GRK2 promoter: An essential GRK2 promoter region has been identified, and it could be shown that stimulation with the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) results in increased GRK2 promoter activity [7] . However, it is unclear which transcription factors regulate GRK2 expression to possible target its activation. Remarkably, the GRK2 promoter activity was shown to be increased following stimulation by PMA as late as after 18 hr, indicating that this late promoter activation was likely be reflected by a transcriptional regulatory mechanism [7] . Interestingly, the transcription factor early-growth response 1 (EGR-1) has a major role in cardiovascular pathobiology [8] and is up-regulated with heart failure [9] . To this, EGR-1 is essential for PMA-induced promoter expression, such as activation of the human Na+/H+ exchanger 3 (NHE3) promoter [10] . Therefore, we speculated that EGR-1 might regulate GRK2 transcription.
Material and Methods
H9c2 rat cardiomyoblast cells (LGC Standards, Wesel, Germany), human embryonic kidney cells (Hek293 cells; DSMZ, Braunschweig, Germany) and A10 cells (DSMZ) were routinely maintained in Dulbecco's modified Eagle's medium (DMEM, high glucose, GlutaMAX; Thermo Fisher Scientific, Massachusetts, USA) supplemented with 10% foetal bovine serum and penicillin/streptomycin in a 5% CO 2 atmosphere at 37°C. mRNA expression analysis. For stimulation experiments with subsequent mRNA expression analysis, H9c2 cells were serum starved for 24 hr and stimulated with PMA (100 nM) or vehicle (DMSO) for the indicated time periods. For experiments with actinomycin D, cells were treated with actinomycin D (5 lg/ml), PMA (100 nM), the inactive PMA analogue 4-a phorbol 12-myristate 13-acetate (4-a PMA, 100 nM), or vehicle (DMSO) for 5 hr. All chemicals were purchased from Sigma Aldrich (Missouri, USA). For quantitative realtime PCR analysis with EGR-1 over-expression, Hek293 cells were seeded and transfected with the EGR-1 expression plasmid pcDNA3.1 or pcDNA3.1_Egr-1. Cloning of the EGR-1 expression plasmid was described previously [11] .
Total RNA was isolated according to the manufacturer's instructions (peqGOLD Micro Spin total RNA Kit; Peqlab, Erlangen, Germany), RNA was reverse transcribed with M-MLV reverse transcriptase (Promega, Madison, WI, USA), qPCR was performed on an Applied Biosystems Step One Plus Real-Time PCR System taking into account several considerations for housekeeping gene selection [12] (see  table 1 , listing all primers used in this study), and relative quantification employed the 2 ÀDCT method [13] .
Study subjects. A Caucasian population sample of 600 consecutive healthy individuals of either sex had been recruited at the Essen University Hospital Blood Transfusion Center [14] , and their DNA was used to identify new GRK2 promoter polymorphisms and to determine their allele frequency.
Identification of the GRK2 G(-43)A polymorphisms. We used DNA from 20 unrelated Caucasian individuals and sequenced the GRK2 promoter with sense primers 5 0 -GTCAGAATCAAGGTTGGGGTCA-3 0 and 5 0 -GGTCGCAGGTCTGGTTCGG-3 0 and antisense primers 5 0 -CGAACCAGACCTGCGACCG-3`and 5 0 -CGGCGTGGCCT-TGCTCTTC-3 0 spanning the GRK2 promoter region from nt-910 until nt+72 (in relation to the translation start point ATG). PCR products were sequenced by an external sequencing service (MWG Eurofins, Ebersberg, Germany).
Genotyping of the GRK2 G(-43)A polymorphism. GRK2 G(-43)A (rs182084609) allele frequency was determined by pyrosequencing in pools of DNA from 600 Caucasian individuals. Therefore, DNA of 50 individuals was pooled and PCR was performed with the primers 5 0 -GGTCGCAGGTCTGGTTCGG-3 0 and biotinylated antisense primer 5 0 -CGGCGTGGCCTTGCTCTTC-3 0 resulting in a 471 bp product following by Pyrosequencing with the sequencing primer 5 0 -CGAGCGAGCAGGAGC-3 0 .
Cloning of GRK2 promoter construct. A GRK2 promoter construct À402/+72 (in relation to the translation start point ATG) was amplified from human DNA with either the A(-43) or the G(-43) allele using a standard PCR including Pfu polymerase with the primers 5 0 -GGTCGCAGGTCTGGTTCGG-3 0 and 5 0 -CGGCGTGGC-CTTGCTCTTC-3 0 , cloned into pGEM T-easy vector (Promega) and sequenced (Eurofins, Ebersberg, Germany), followed by sub-cloning the fragment into the pGL4.10 vector (Promega, Mannheim, Germany) and re-sequencing the construct. The construct was designated as pGL4.10_GRK2.
In silico analysis of putative EGR-1 binding to the GRK2 promoter. Analysis of putative EGR-1 binding was done with the software tool MatInspector (www.genomatix.de). The respective algorithm [15] estimates the likelihood of transcription factor binding to a given target nucleotide sequence using a library of weight matrices. If each sequence position in the target sequence corresponds to the highest conserved nucleotide at that position in the matrix, there is a perfect match to the matrix, being expressed with a 'matrix similarity' score of 1.00. A good match has a similarity of >0.80. GRK2, G-protein coupled receptor kinase 2; EGR-1, early-growth response 1; ACTB, actin beta. 1 Human ACTB primer as described [41] .
Luciferase assays with pcDNA3.1 and pcDNA3.1_Egr-1 transfection were performed as described above with the exception that cells were transfected with 52.5 ng of Firefly reporter vector pGL4.10, 17.5 ng of Renilla luciferase vector pGL4.74, and 70 ng pcDNA3.1 or pcDNA3.1_Egr-1.
Electrophoretic mobility shift assays. Nuclear extracts were isolated from Hek293 cells transfected with pcDNA3.1 or pcDNA3.1_Egr-1 using the Cellytic NuCLEAR Extraction Kit (Sigma, Deisenhofen, Germany) and stored at À80°C until use. EMSAs were performed with the DIG Gel Shift kit (Roche Applied Sciences, Mannheim, Germany) using digoxigenin (DIG)-labelled double-stranded oligonucleotides which were derived from synthesized oligonucleotides. Nucleotide sequences of the sense strand of the double-stranded oligonucleotides were as follows: Oligo A(-43): 5 0 -GCGAGCAGGAGCGGCAGCGGCGGCGGCGGC-3 0 and Oligo G(-43): 5 0 -GCGAGCAGGAGCGGCGGCGGCGGCGGCGGC-3 0 . Sense and antisense oligonucleotides were DIG-labelled, and probes were incubated with 10-lg nuclear extracts for 20 min. at room temperature. For competition analysis, 1259 unlabelled probe was added. The samples were then subjected to non-denaturating 4-6% polyacrylamide gel electrophoresis. DNA-protein complexes were electroblotted to positively charged nylon membranes (Roche Applied Sciences), and band shifts were visualized according to the manufacturer's manual.
Statistical analysis. Data are presented as means AE standard deviation and were analysed using GraphPad Prism 6 (Graph Pad Software, La Jolla, CA, USA). mRNA expression analysis of cell cultures and luciferase assays were performed in duplicate and repeated at least three times. Data from Luciferase Assays were compared with Student's t-test for unpaired samples. In mRNA expression analysis, comparison of values from two groups was performed with the Wilcoxon matched pairs signed-rank test and by repeated-measure ANOVA with Holm-Sidak's correction for multiple testing for more than two groups. An a priori alpha error p of less than 0.05 was considered to indicate statistical significance. A P value of less than 0.05 is marked with one asterisk (*), a P value of less than 0.01 is marked with two asterisks (**), and a P value of less than 0.001 is marked with three asterisks (***).
Results
Grk2 and Egr-1 mRNA expression analysis following PMA stimulation. We evaluated endogenous expression profiles of Egr-1 and Grk2 mRNA expression in H9c2 cells following stimulation with 100 nM PMA ( fig. 1A,B) . Egr-1 mRNA expression increased immediately 1 hr after PMA stimulation, and the highest Egr-1 expression was detected at this time (p = 0.0003). Egr-1 mRNA expression then decreased rapidly and was close to control values 4 hr after PMA stimulation ( fig. 1A ). Grk2 mRNA expression increased slowly following PMA stimulation and showed a 1.5-fold increased expression not until 5 hr after PMA stimulation (4 hr: p = 0.016, 5 hr: p = 0.008; fig. 1B ).
To investigate whether increased Grk2 mRNA expression following PMA stimulation is a specific effect of PMA, we also stimulated cells with 4a-PMA, an inactive PMA analogue. In contrast to the up-regulation of Grk2 mRNA expression evoked by PMA, no significant change was seen with 4a-PMA. Likewise, co-stimulation with PMA and the transcription inhibitor Actinomycin D did not change Grk2 mRNA expression, indicating that a transcription-driven mechanism evokes Grk2 up-regulation by PMA ( fig. 1C) .
Sequencing, cloning and characterization of the GRK2 promoter. The nucleotide sequence of the genomic DNA upstream of the human GRK2 translation start site is shown in fig. 2A .
No further polymorphisms were identified. In silico analysis (www.genomatix.de) revealed four GRK2 promoter regions with putative EGR-1-binding sites ( fig. 2A) . Interestingly, one of these regions surrounded the G(-43)A polymorphism. There were three predicted binding sites in the presence of the G(-43) allele (matrix similarity: 0.794, 0.898 and 0.91) compared with just one predicted binding site in the presence of the A(-43) allele (matrix similarity: 0.889) ( fig. 2A) .
The cloned wild-type GRK2 promoter construct with the G(-43) allele showed a high level of promoter activity after 24 hr in H9c2, Hek293 and A10 cells ( fig. 2B ). There was no statistical difference between the construct with the G(-43) and the A(-43) allele in Hek293 cells ( fig. 3A ). In EMSAs with nuclear extracts of Hek293 cells, there was specific transcription factor binding both to the G(-43) and the A(-43) oligonucleotide, suggesting binding of transcription factors necessary for maintenance of basal promoter activity ( fig. 3B ).
Regulation of GRK2 transcription by EGR-1.
To determine whether EGR-1 induces GRK2 promoter activity, Hek293 cells were transfected with the GRK2 promoter construct together with either pcDNA3.1 or pcDNA3.1_Egr-1 ( fig. 4A ). EGR-1 led to a stronger increase in GRK2 promoter activity in the promoter construct containing the G(-43) allele as compared with the A(-43) allele (p = 0.04, fig. 4A ). EGR-1 increased GRK2 promoter activity in the presence of the G(-43) allele more 2.2-fold, whereas increase in the presence of the A(-43) allele was only 1.6-fold.
In EMSA experiments with EGR-1 over-expression ( fig. 4B) To investigate whether EGR-1 results in increased GRK2 expression, Hek293 cells were transfected with pcDNA3.1 or pcDNA3. 1_Egr-1 (fig. 4C ). EGR-1 over-expression increased GRK2 mRNA expression by 20% (p = 0.03).
Therefore, by means of the naturally occurring variant, the G(-43)A polymorphism, we can demonstrate that Egr-1 regulates GRK2 transcription. (A) Egr-1 mRNA expression was determined at each time point and normalized to actin beta (Actb). Expression levels of unstimulated solvent controls were set to 1 at each time point. Given is the control (Ctrl.) (unstimulant solvent) at 1 hr. Experiments were repeated three times and mRNA expression analysis was performed in duplicates. Post hoc: Ctrl 1 hr versus 1 hr, p = 0.0003. (B) Grk2 mRNA expression was determined at each time point and normalized to Actb. Expression levels of unstimulated solvent controls were set to 1 at each time point. The control (unstimulant solvent) at 1 hr is provided. Experiments were repeated three times, and mRNA expression analysis was performed in duplicates. Post hoc: Ctrl. 1 hr versus 4 hr, p = 0.016, and Ctrl. 1 hr versus 5 hr, p = 0.008. (C) H9c2 cells were stimulated with phorbol 12-myristate 13-acetate (PMA), the inactive PMA analogue 4-a phorbol 12-myristate 13-acetate (4a-PMA), PMA plus actinomycin D (ActD), ActD, or solvent (DMSO) for 4 hr and Grk2 mRNA expression was determined. The Grk2 expression was normalized to Actb. DMSO and ActD controls were set to 1. All experiments were repeated three times and mRNA expression analysis was performed in duplicates. (*) = p value < 0.05, (**) = p value < 0.01, and (***) = p value < 0.001.
Discussion
In this study, we aimed to clarify molecular mechanisms regulating GRK2 transcription. This is of great clinical importance since up-regulation of GRK2 is associated with myocardial dysfunction and heart failure [16] and the inhibition of GRK2 has become an interesting therapeutic approach in heart failure [6, 17] . We speculated that the transcription factor EGR-1 might be involved in GRK2 transcription and could show an immediate up-regulation of Egr-1 and subsequently of Grk2 mRNA expression after PMA stimulation. To this, we demonstrated a direct interaction between EGR-1 and the GRK2 promoter ( fig. 4B ) with subsequent consequences for GRK2 promotor activity ( fig. 4A) and gene expression (fig. 4C). 
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Fig. 2. (A) Sequence and characterization of the 5
0 -flanking region of the human GRK2 gene. The translation starting point is marked by an arrow. The numbers on the left correspond to the translational starting point ATG. Bold letters: Primer binding sites for cloning the nt-402/+72 GRK2 promoter construct. Underlined letters: GRK2 promoter regions with putative EGR-1 binding sites (www.genomatrix.de). Cursive letters correspond to the EMSA oligonucleotides surrounding the predicted EGR-1 binding sites within the G(-43)A polymorphism. Furthermore, the predicted EGR-1 binding to the EMSA oligonucleotides with the alternatives alleles is given as evaluated by in silico analysis (www.genomatrix.de). Three putative binding sites were predicted in the presence of the G(-43) allele (marked with I, II and III), whereas only one putative binding site was predicted in the presence of the A(-43) allele (marked with I). The EGR-1 core sequence is marked with capital letters and the associated matrix similarity (Matrix sim.) is given (www.genomatrix.de). (B) Determination of basal promoter activity of the GRK2 promoter. H9c2, Hek293 and A10 cells were transfected for 24 hr with GRK2 promoter-pGL4.10 constructs (nt-402/+72) with wild-type G(-43) allele providing expression of Firefly luciferase (start of luc gene expression is marked with an arrow) under the control of the GRK2 promoter construct and the pGL4.74 vector which provides constitutive expression of Renilla luciferase as an internal control. Ratios are expressed as Firefly/Renilla. Luciferase Assays were repeated at least three times. Numbers refer to translation initiation point (TSS).
Thereby, we identified EGR-1 as a regulator of GRK2 transcription, and this molecular mechanism might be a promising target to mitigate adrenergic desensitization.
The EGR-1 protein is the product of an immediate early gene [18] , a key player in myocardial cell injury [19] , and its expression is increased in heart failure [9] . EGR-1 supposedly functions as a master switch activated by ischaemia to trigger expression of pivotal regulators of inflammation, coagulation and vascular hyperpermeability [20] . In a pig model of myocardial ischaemia/reperfusion injury, EGR-1 silencing by intracoronary delivery of a targeting DNAzyme at the time of reperfusion following acute myocardial ischaemia decreased myocardial inflammation and apoptosis and improved cardiac function [21] . Therefore, silencing Egr-1 might represent an opportunity to interrupt gene signalling and potentially attenuate myocardial damage. A specific endogenous EGR-1 inhibitor, Nab1, was A B Fig. 3. (A) Determination of basal promoter activity of the GRK2 promoter. Hek293 cells were transfected for 24 hr with GRK2 promoterpGL4.10 constructs (nt-402/+72) with either the G(-43) or the A(-43) allele providing expression of Firefly luciferase (start of luc gene expression is marked with an arrow) under the control of the GRK2 promoter construct and the pGL4.74 vector which provides constitutive expression of Renilla luciferase as an internal control. Ratios are expressed as Firefly/Renilla. Luciferase assays were repeated at least three times. Numbers refer to translation initiation point (TSS). (B) Electrophoretic mobility shift assay: Hek293 nuclear extracts were incubated with oligonucleotides spanning the GRK2 promoter region nt-59/-29 with the GG or the AA allele at position nt-43 in the absence or presence of a molar excess of unlabelled probe. Specific (sp.) and unspecific (unsp.) bands are marked with an arrow.
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found to function as a regulator of cardiac growth [22] . Cardiac over-expression of Nab1 in transgenic mice selectively suppressed adrenergically mediated cardiac hypertrophy and the cardiac hypertrophic response associated with myocardial pressure overload but left physiological ventricular growth during development and physical training unaffected [22] . However, EGR-1 is involved in the regulation and expression of more than 300 genes [23] , arguing against a potential use of EGR-1 inhibition to mitigate adrenergic desensitization.
For GRK2 inhibition, different compounds have been developed for pharmacological inhibition or gene therapy [6] . For example, paroxetine, originally developed as an anti-depressive agent, and shown to inhibit GRK2 [24] , reverses cardiac dysfunction and remodelling after myocardial infarction in mice [25] . In humans, paroxetine was shown to be effective in improving cardiac function in patients with acute myocardial infarction and depression and these findings correlated with a decrease in GRK2 expression [26] . However, as indicated by both in vitro and in vivo studies, although paroxetine has demonstrated a good degree of selectivity for GRK2, a high dosage is needed to efficiently work, thus limiting any future clinical application [27] . There are several other GRK2-targeting compounds in pre-clinical studies [6] ; however, the optimal drug has not been identified yet.
Therefore, a differential blockade of EGR-1 binding to certain genes identified in cardiac pathological signalling pathways might be reasonable. Beyond blockade of EGR-1 binding to GRK2, EGR-1 binding to mediators of cardiac hypertrophy, such as G q [28] , G 11 [11] and the downstream effector phospholipase C beta 1 [29] , might be useful. In this regard, it is interesting that EGR-1 represents the transcriptional step required for PMA-induced GRK2 promoter activation. This has also been demonstrated for other promoters, such as activation of the NHEM3 or the FLT-1 promoter [10, 30] . PMA mimics the action of diacylglycerol, which is produced in cells on stimulation of phospholipase C. Several G-protein-coupled receptors that mediate the action of key cardiovascular messengers modulate phospholipase C beta activity through stimulation of G q [31] . Therefore, it might be speculated that G q signalling pathways are able to increase the transcriptional activity of the GRK2 promoter. To this, Endothelin-1 or Angiotensin-II transmit their signals via G qcoupled receptors, and their expression is not only modulated in heart failure and cardiac hypertrophy, but these hormones also regulate or are regulated by EGR-1 [32] [33] [34] . This again underscores that EGR1 is an important master gene altered in heart failure and cardiac hypertrophy and that specific blockade of EGR-1 binding to certain genes identified in these both pathways might be reasonable.
Blockade of EGR-1 binding has been investigated in vitro in various cell types. In cardiomyocytes, mutation of the EGR-1 consensus sequence in the Fibroblast growth factor-2 (FGF-2) promoter abolished a-adrenergic responsiveness [35] . However, to our knowledge, an inhibition of specific EGR-1-binding sites in certain genes has not been investigated so far.
Recent studies suggest that GRK2 can signal independently from GPCRs in a 'non-canonical' manner [5] , and it is assumed that GRK2 simultaneously modulates several cardiovascular regulatory pathways, including GPCRs and insulin signalling cascades, NO bioavailability and mitochondrial function, which may help to explain not only the contribution to maladaptive cardiovascular function but also unveil GRK2 as a link between cardiovascular pathologies and co-morbidities such as obesity or type 2 diabetes [36] . Interestingly, EGR-1 is also involved in the development of obesity and type 2 diabetes [37, 38] . Therefore, a mutation of EGR-1 binding sites in the GRK2 promoter in other tissues might also attenuate these co-morbidities.
We investigated the regulation of GRK2 transcription by EGR-1 with a naturally occurring variant, the G(-43)A polymorphism. Minor A allele frequency was low (0.02), which is in line with a reported minor A allele frequency of 0.015 in Caucasian individuals [39] . Despite differences in reported minor A allele frequencies in other ethnicities, being 0.001 in the African and 0 in the east Asian population [39], we believe that the clinical impact of this polymorphism is rather small due to low minor A allele frequency.
However, this polymorphism surrounding an EGR-1 binding site presents a suitable target for inhibition of EGR-1 binding to the GRK2 promoter while further putative EGR-1 binding sites in the essential GRK2 promoter region have been predicted, so that it is possible that a mutation of also other EGR-1 binding sites is necessary to completely abolish GRK2 activation.
Interestingly, it could be demonstrated that GRK2 overexpression inhibits IGF1-induced proliferation and migration of human hepatocellular carcinoma cells by down-regulating EGR-1 [40] . Therefore, it might be possible that there exists a feedback mechanism between GRK2 and EGR-1 to possibly inhibit GRK2 over-expression with subsequent consequences. Whether these feedback mechanisms also apply in cardiovascular disease should be investigated in future studies.
In conclusion, by means of a naturally occurring variant, the G(-43)A polymorphism, we identified EGR-1 as a regulator of GRK2 transcription. These results possibly provide information about molecular mechanisms of GRK2 regulation. Suppression of GRK2 expression by inhibition of Egr-1 binding to GRK2 might be a promising approach to mitigate adrenergic desensitization.
